News Pfizer offers $60m to settle prescriber kickback claims Pfizer has paid $60m to settle US government allegations that its Biohaven unit made improper payments to prescribers of its migraine drug Nurtec ODT.
News Pfizer’s migraine push builds with Zavzpret nod Zavzpret is first CGRP to be approved in a nasal formulation designed to be rapid acting.
News AbbVie files Qulipta for chronic migraine prevention AbbVie has filed for approval of its oral CGRP inhibitor Qulipta for prevention of chronic migraine, seeking to leap ahead of its main rival in the class.
Oncology Servier’s ASCO 2025 Data: Advancing IDH-Mutated Cancer Treat... At ASCO 2025, Servier’s Becky Martin discusses IDH-mutated cancers, including key insights on Tibsovo & Voranigo, and the implications for patients.